arrow
J

Jennifer Hughes

stellenbosch university
H指数:27
被引数:3,562

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pharmacokinetics and Safety of a Novel Clofazimine Formulation and Dosing Strategy in Children With Rifampicin-resistant Tuberculosis

新型氯法齐明制剂及其给药方案在利福平耐药结核患儿中的药代动力学和安全性

2026-08-130
OAAI
Maternal, Pregnancy, and Infant Outcomes in Women Treated for Multidrug-Resistant/Rifampicin-Resistant Tuberculosis With Novel and Repurposed Drugs in KwaZulu-Natal, South Africa

南非夸祖鲁-纳塔尔省接受新型和再利用药物治疗耐多药/利福平耐药结核病女性的母婴及婴儿结局

2025-11-010
OAAI
Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s

氯法齐明在利福平耐药结核病孕妇及产后妇女中的药代动力学与安全性:IMPAACT P1026s研究的结果

2025-10-010
PRE
Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis

对接触耐多药或耐利福平结核分枝杆菌的个体的管理

2025-06-060
PRE
Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s

左氧氟沙星治疗利福平耐药结核病在孕期及产褥期的药代动力学与安全性:IMPAACT P1026s研究的结果

2025-03-280
OA
Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study
2022-07-0139
OAAI
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study
2022-04-0166
OAAI